Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Key drivers include Breztri Aerosphere (budesonide, formoterol fumarate, and glycopyrrolate) and Fasenra, both of which are positioned for indication expansions into severe asthma and COPD.

“People who have chronic obstructive pulmonary disease (COPD) will be able to access budesonide, glycopyrronium, and formoterol ‘triple inhaler’ (branded as Breztri Aerosphere) from today as ...

AZ is also developing a rival triple therapy inhaler, Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), which is already approved in the US in COPD and is in late-stage ...

Pharmac’s achievements as historic funding enable access to new, life-saving medicines for New Zealanders, Associate Health Minister David Seymour said. Pharmac, New Zealand's medicine ...